Drug Trial Radar · NCT07901114
A Bioequivalence and Safety Study of AJU-C719 and C719R in Healthy Adult Volunteers
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- AJU Pharm Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the bioequivalence and safety of "AJU-C719" and "C719R" in healthy adult subjects.
Conditions
- Hypertension
Interventions
Test DrugDrug
AJU-C719
Reference DrugDrug
C719R
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUCt of AJU-C719Time frame: Pre-dose(0 hours) ~ 72 hours
- Cmax of AJU-C719Time frame: Pre-dose(0 hours) ~ 72 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bumin Hospital (Seoul)
Seoul, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.